Corcept Therapeutics Faces Securities Class Action Due to FDA Rejection and Patent Loss
Corcept Therapeutics in Legal Hot Water: A Class Action Lawsuit Unfolds
In a significant development for investors, Corcept Therapeutics Incorporated (NASDAQ: CORT) has come under scrutiny as the national law firm Hagens Berman has alerted shareholders about an ongoing securities class action. The action follows the recent rejection of a key drug application by the FDA, alongside the loss of an important patent in a federal court. The lawsuit alleges that Corcept management concealed critical information about the FDA's concerns regarding their drug candidate, relacorilant.
The Legal Landscape
The class action, titled Allegheny County Employees' Retirement System v. Corcept Therapeutics Inc., et al., was filed in the U.S. District Court for the Northern District of California. The plaintiffs in the case are seeking to recover losses incurred by investors who purchased Corcept's common stock between October 31, 2024, and December 30, 2025, a period now referred to as the
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.